126 related articles for article (PubMed ID: 38710206)
1. Pentoxifylline as a Novel Add-on Therapy for Major Depressive Disorder in Adult Patients: A Randomized, Double-Blind, Placebo-Controlled Trial.
Merza Mohammad TA; Merza Mohammad TA; Salman DM; Jaafar HM
Pharmacopsychiatry; 2024 May; ():. PubMed ID: 38710206
[TBL] [Abstract][Full Text] [Related]
2. The Phosphodiesterase Inhibitor Pentoxifylline as a Novel Adjunct to Antidepressants in Major Depressive Disorder Patients: A Proof-of-Concept, Randomized, Double-Blind, Placebo-Controlled Trial.
El-Haggar SM; Eissa MA; Mostafa TM; El-Attar KS; Abdallah MS
Psychother Psychosom; 2018; 87(6):331-339. PubMed ID: 30205379
[TBL] [Abstract][Full Text] [Related]
3. Effect of celecoxib add-on treatment on symptoms and serum IL-6 concentrations in patients with major depressive disorder: randomized double-blind placebo-controlled study.
Abbasi SH; Hosseini F; Modabbernia A; Ashrafi M; Akhondzadeh S
J Affect Disord; 2012 Dec; 141(2-3):308-14. PubMed ID: 22516310
[TBL] [Abstract][Full Text] [Related]
4. Palmitoylethanolamide as adjunctive therapy in major depressive disorder: A double-blind, randomized and placebo-controlled trial.
Ghazizadeh-Hashemi M; Ghajar A; Shalbafan MR; Ghazizadeh-Hashemi F; Afarideh M; Malekpour F; Ghaleiha A; Ardebili ME; Akhondzadeh S
J Affect Disord; 2018 May; 232():127-133. PubMed ID: 29486338
[TBL] [Abstract][Full Text] [Related]
5. The Antidiabetic Metformin as an Adjunct to Antidepressants in Patients with Major Depressive Disorder: A Proof-of-Concept, Randomized, Double-Blind, Placebo-Controlled Trial.
Abdallah MS; Mosalam EM; Zidan AA; Elattar KS; Zaki SA; Ramadan AN; Ebeid AM
Neurotherapeutics; 2020 Oct; 17(4):1897-1906. PubMed ID: 32500486
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of tipepidine as adjunctive therapy in major depressive disorder: A randomized, double-blind, placebo-controlled clinical trial.
Hoobehfekr S; Moghaddam HS; Shalbafan M; Hashemi MG; Pirmoradi MM; Sakenian A; Poopak A; Kashefinejad S; Yarahmadi M; Akhondzadeh S
Psychiatry Clin Neurosci; 2021 Feb; 75(2):57-62. PubMed ID: 33247483
[TBL] [Abstract][Full Text] [Related]
7. BDNF, interleukin-6, and salivary cortisol levels in depressed patients treated with desvenlafaxine.
Ninan PT; Shelton RC; Bao W; Guico-Pabia CJ
Prog Neuropsychopharmacol Biol Psychiatry; 2014 Jan; 48():86-91. PubMed ID: 24096053
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of pentoxifylline combination therapy in major depressive disorder: a randomized, double-blind, placebo-controlled clinical trial.
Farajollahi-Moghadam M; Sanjari-Moghaddam H; Ghazizadeh Hasemi M; Sanatian Z; Talaei A; Akhondzadeh S
Int Clin Psychopharmacol; 2021 May; 36(3):140-146. PubMed ID: 33724254
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness of low doses of paroxetine controlled release in the treatment of major depressive disorder.
Trivedi MH; Pigotti TA; Perera P; Dillingham KE; Carfagno ML; Pitts CD
J Clin Psychiatry; 2004 Oct; 65(10):1356-64. PubMed ID: 15491239
[TBL] [Abstract][Full Text] [Related]
10. Pioglitazone adjunctive therapy for moderate-to-severe major depressive disorder: randomized double-blind placebo-controlled trial.
Sepanjnia K; Modabbernia A; Ashrafi M; Modabbernia MJ; Akhondzadeh S
Neuropsychopharmacology; 2012 Aug; 37(9):2093-100. PubMed ID: 22549115
[TBL] [Abstract][Full Text] [Related]
11. Double-blind, randomized, placebo-controlled pilot study of the phosphodiesterase-3 inhibitor cilostazol as an adjunctive to antidepressants in patients with major depressive disorder.
Abdallah MS; Ramadan AN; Omara-Reda H; Mansour NO; Elsokary MA; Elsawah HK; Zaki SA; Abo Mansour HE; Mosalam EM
CNS Neurosci Ther; 2021 Dec; 27(12):1540-1548. PubMed ID: 34545997
[TBL] [Abstract][Full Text] [Related]
12. Quetiapine as combination treatment with citalopram in unipolar depression with prominent somatic symptoms: a randomised, double-blind, placebo-controlled pilot study.
Quante A; Regen F; Schindler F; Volkmer K; Severus E; Urbanek C; Luborzewski A; Roepke S; Anghelescu I
Psychiatr Danub; 2013 Sep; 25(3):214-20. PubMed ID: 24048387
[TBL] [Abstract][Full Text] [Related]
13. L-Carnosine combination therapy for major depressive disorder: A randomized, double-blind, placebo-controlled trial.
Araminia B; Shalbafan M; Mortezaei A; Shirazi E; Ghaffari S; Sahebolzamani E; Mortazavi SH; Shariati B; Ardebili ME; Aqamolaei A; Naderi S; Akhondzadeh S
J Affect Disord; 2020 Apr; 267():131-136. PubMed ID: 32063564
[TBL] [Abstract][Full Text] [Related]
14. Bupropion extended release compared with escitalopram: effects on sexual functioning and antidepressant efficacy in 2 randomized, double-blind, placebo-controlled studies.
Clayton AH; Croft HA; Horrigan JP; Wightman DS; Krishen A; Richard NE; Modell JG
J Clin Psychiatry; 2006 May; 67(5):736-46. PubMed ID: 16841623
[TBL] [Abstract][Full Text] [Related]
15. Pentoxifylline for treatment of major depression after percutaneous coronary intervention or coronary artery bypass grafting: A randomized, double-blind, placebo-controlled trial.
Yasrebi SO; Momtazmanesh S; Moghaddam HS; Shahmansouri N; Mehrpooya M; Arbabi M; Ghazizadeh-Hashemi F; Akhondzadeh S
J Psychosom Res; 2021 Nov; 150():110635. PubMed ID: 34627009
[TBL] [Abstract][Full Text] [Related]
16. Novel Augmentation Strategies in Major Depression.
Martiny K
Dan Med J; 2017 Apr; 64(4):. PubMed ID: 28385173
[TBL] [Abstract][Full Text] [Related]
17. Ziprasidone Augmentation of Escitalopram for Major Depressive Disorder: Efficacy Results From a Randomized, Double-Blind, Placebo-Controlled Study.
Papakostas GI; Fava M; Baer L; Swee MB; Jaeger A; Bobo WV; Shelton RC
Am J Psychiatry; 2015 Dec; 172(12):1251-8. PubMed ID: 26085041
[TBL] [Abstract][Full Text] [Related]
18. Venlafaxine extended release versus citalopram in patients with depression unresponsive to a selective serotonin reuptake inhibitor.
Lenox-Smith AJ; Jiang Q
Int Clin Psychopharmacol; 2008 May; 23(3):113-9. PubMed ID: 18408525
[TBL] [Abstract][Full Text] [Related]
19. Extended-release quetiapine as adjunct to an antidepressant in patients with major depressive disorder: results of a randomized, placebo-controlled, double-blind study.
Bauer M; Pretorius HW; Constant EL; Earley WR; Szamosi J; Brecher M
J Clin Psychiatry; 2009 Apr; 70(4):540-9. PubMed ID: 19358791
[TBL] [Abstract][Full Text] [Related]
20. Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies.
Tourian KA; Padmanabhan SK; Groark J; Brisard C; Farrington D
Clin Ther; 2009 Jun; 31 Pt 1():1405-23. PubMed ID: 19698901
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
